Outset Medical Reports Q3 2026 Revenue Growth and 40.7% Gross Margin

Outset Medical reported third-quarter 2026 revenue of $33.6 million, up 14% year over year, and gross margin of 40.7%. The company recorded a GAAP net loss of $14.7 million and non-GAAP diluted net loss per share of $0.68. Outset reiterated its 2026 revenue guidance of $125 million to $130 million.

Financial Highlights

• Revenue: $33.6 million, up 14% from $29.4 million in the third quarter of 2025.
• Gross profit and margin: Gross profit was $13.7 million, with a 40.7% GAAP gross margin, compared with $11.6 million and 39.4% a year earlier. Non-GAAP gross margin was 40.8%.
• Operating loss: $12.3 million, compared with $15.8 million in the prior-year quarter.
• Net loss and adjusted diluted EPS: GAAP net loss was $14.7 million, versus $17.8 million; non-GAAP diluted net loss per share was $0.68, compared with $0.69.
• Cash and outlook: Cash, cash equivalents, short-term investments and restricted cash totaled $140.7 million at quarter end. Outset reiterated 2026 revenue guidance of $125 million to $130 million and expects full-year non-GAAP gross margin in the low-40% to mid-40% range.

Business Highlights

• Management cited strong customer satisfaction and retention as supporting broader Tablo adoption among existing customers.
• The company said Tablo adoption is helping fuel new insourced dialysis partnerships with leading health systems.
• Tablo is FDA-cleared for use from hospital to home and is used at more than 1,000 U.S. healthcare facilities.
• The integrated system combines water purification and on-demand dialysate production and connects with electronic medical record systems and Outset’s data analytics platform.

Original SEC Filing: Outset Medical, Inc. [ OM ] - 8-K - Nov. 04, 2026